bluebird bio (BLUE) PT Raised to $83 at BMO as bb2121 Shows Promising Efficacy, Clean Safety
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
bluebird bio Announces Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate in Patients with Relapsed/Refractory Multiple Myeloma
November 30, 2016 5:27 PM EST100% of patients (n=6) in second and third dose cohorts achieved an objective response; two patients MRD-negative; overall response rate (ORR) is 78%
Two patients achieved stringent complete responses, with 6 and 4 months follow-up
Among all dosed patients (n=11), no dose-limiting toxicities to date, no Grade 3 or Grade 4 cytokine release syndrome or Grade 3 or Grade 4 neurotoxicity observed
Company to hold conference call and webcast with slides at 8:00 am ET on Thursday, December 1st
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc.... More
